COVID-19. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group will receive 100 mg thalidomide tablets made by Kobel Daru Company orally for 14 days along with other routine treatments for pneumonia cause
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Definitive laboratory results for Covid-19 Radiographic results of lung injury and infection Less than 5 days have passed since the confirmation of the infection Moderate disease severity based on the World Health Organization classification criteria
Exclusion criteria
Exclusion criteria: Pregnancy Breastfeeding Receive thalidomide or other experimental drugs related to the treatment of Covid-19 within one month prior to enrollment Existence of a history of thromboembolism unrelated to recent Covid-19 disease History of interstitial lung disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete clinical recovery time. Timepoint: After interventions. Method of measurement: Examination and clinical signs.;Mortality rate. Timepoint: After interventions. Method of measurement: Patients' records. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactGhasem Mohammadsharifi
Esfahan University of Medical Sciences
Outcome results
None listed